Recent News

• 06.11.2025 - Goldman Sachs 46th Annual Global Healthcare Conference
• 06.11.2025 - Goldman Sachs 46th Annual Global Healthcare Conference
• 06.05.2025 - Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025
• 06.05.2025 - Upstream Bio to Present Mechanistic Insights into Verekitug’s Enhanced Potency via TSLP Receptor Targeting at European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025
• 06.04.2025 - Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
• 06.04.2025 - Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
• 05.20.2025 - Upstream Bio Appoints Stacy Price as Chief Technology Officer
• 05.20.2025 - Upstream Bio Appoints Stacy Price as Chief Technology Officer
• 05.06.2025 - Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs
• 05.06.2025 - Upstream Bio Reports First Quarter 2025 Financial Results and Accelerates Guidance on All Clinical Programs

Recent Filings

• 05.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.06.2025 - EX-99.1 EX-99.1
• 05.06.2025 - 8-K Current report
• 04.17.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.17.2025 - DEF 14A Other definitive proxy statements
• 04.17.2025 - ARS Annual Report to Security Holders